Viatris Inc at Raymond James Institutional Investors Conference Transcript
Good afternoon. Welcome to the Viatris presentation at Raymond James' 43rd Annual Institutional Investor Conference. Viatris is an emerging global pharmaceutical leadership name, formed via the combination of Pfizer's legacy Upjohn business and Mylan's global generics and specialty branded products business.
From the company here today, CEO, Michael Goettler; CFO; Sanjeev Narula. Michael?
Yes. Thank you, Elliot, and thanks for inviting us. Just wanted for those that are not that familiar with the name, summarize a little bit. We had -- about a week ago, we had an investor event, and I just want to summarize what we announced.
We announced, number one, a deal with Biocon Biologics on combining our biosimilar business in return for up to $3.335 billion, $2 billion upfront and then some participation in 12.9% stake in the future company. That's a deal that is, number one, creating a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
